TX HB2528

Prohibits health benefit plans from requiring prior authorization for medication-assisted treatment (MAT) of opioid or substance use disorders, except to prevent fraud, waste, and abuse

Covers specific MAT medications including methadone, buprenorphine, buprenorphine/naloxone, and naltrexone

Applies broadly to insurance companies, HMOs, group hospital service corporations, multiple employer welfare arrangements, small employer health plans, and self-funded plans sponsored by professional employer organizations

Exempts state Medicaid programs (including Medicaid managed care) and the Children's Health Insurance Program (CHIP) from these requirements

Takes effect September 1, 2025, applying to health benefit plans delivered, issued, or renewed on or after January 1, 2026